← All trials
NCT01440751
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2010
- Primary completion
- Dec 1, 2013
- Completion date
- Dec 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 94
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Aeon Astron Europe B.V.Lead sponsor
- Glaucoma Associates of New YorkOverall official - principal investigator
- Northwestern UniversityStudy director
- Dean McGee Eye InstituteStudy director
- Boozman-Hof Eye ClinicStudy director
- Glaucoma Associates of TexasStudy director
- The New York Eye & Ear InfirmaryCollaborator
- Glaucoma Associates of New YorkCollaborator
- Thomas Jefferson UniversityStudy director
- Icahn School of Medicine at Mount SinaiStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.